Moderna MRNA · USD
Health Care · Biotechnology · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
199.33
+1.29%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $79.09bn
- Last close × shares
- Volume
- 8.2m
- Shares, 19 Nov 2026
About Moderna
From its filings with the US Securities and Exchange Commission
Moderna is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MRNA. It is a member of the S&P 500 and Nasdaq-100. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $1.94bn and a net loss of $2.82bn. At that date it held total assets of $12.34bn and shareholders' equity of $8.65bn. By region, United States accounted for 61.7%, followed by Rest of world at 35.6% and Europe at 2.7%.
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more.
With a global team and a unique culture, driven by our values and mindsets, our mission is to deliver the greatest possible impact to people through mRNA medicines.
We currently have three commercial products—Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory syncytial virus (RSV)). mNEXSPIKE, which we launched commercially in the third quarter of 2025, is now our leading product in the U.S. retail channel. In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines.
Beyond our commercial products, we continue to demonstrate the potential of our platform technology and are advancing a pipeline of development candidates across oncology, rare disease and infectious disease. In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran autogene (mRNA-4157), our mRNA-based individualized neoantigen therapy, in combination with Merck’s pembrolizumab (KEYTRUDA®), which demonstrated sustained improvement in recurrence-free survival in patients with high-risk melanoma (stage III/IV) following complete resection.
Quoted from its 10-K, filed 20 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2025
- Net product sales $1.82bn · 93.5%
- COVID $1.81bn · 93.1%
- Other revenue $126.0m · 6.5%
- Stand-ready manufacturing revenue $80.0m · 4.1%
Latest on Moderna
Our reporting
Next results
Due on 12 Feb 2027. Analysts expect earnings of -2.07 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Moderna's ticker?
Moderna trades as MRNA on its US listing, under ISIN US60770K1079.
What was Moderna's last closing price?
199.33 on 19 Nov 2026. The figure is in USD and is never converted.
When does Moderna next report results?
Results are expected on 6 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.